Business Wire

CapVest Acquires Second Nature Brands, the US Based Creator of Premium Snacks and Treats

26.4.2022 15:32:00 EEST | Business Wire | Press release

Share

Funds managed by CapVest Partners LLP (“CapVest”), a leading international private equity investor, have closed the acquisition of Second Nature Brands (“the Company”), a Michigan-based creator of premium, nutritional and better for you snacks and treats, including Kar’s Nuts, Second Nature Snacks, and Sanders Chocolates, from a private equity fund affiliated with Palladium Equity Partners, LLC.

With a heritage stretching over 140 years, the Company is a leader in the fast-growing snacks and treats market, focussing on the nutritional and lifestyle needs of health-conscious consumers. The Company’s brands comprise Kar’s Nuts, the #1 branded trail mix delivering better-for-you, on-the-go fuelling snacks, Second Nature Snacks, a pioneer in natural, non-GMO-verified premium snacks and trail mixes created for a healthy, on-the-go lifestyle, and Sanders Chocolates, the leader in premium, small-batch, kettle-cooked sea salt caramels.

Commenting on the transaction, Othmane Khelladi, Partner, CapVest, said: “Second Nature Brands is a very exciting platform with ambitious plans to grow its presence in the highly attractive snacking and treats market. Through our ownership, we look forward to supporting Vic Mehren and his world-class team in accelerating growth through further investment in product innovation, category leadership and by scaling the existing platform through transformational acquisitions.”

Commenting on behalf of Second Nature Brands, CEO Vic Mehren said: “Our partnership with Palladium has been extraordinarily successful and we thank them for their contributions to Second Nature Brands. With their support, and through the efforts of our great Second Nature Brands team members, Second Nature Brands has transformed into a leader within Snacks and Treats. We’re now thrilled to be partnering with CapVest for our next phase of growth. The CapVest team’s deep consumer food experience will be invaluable as we work to build on our Snacks and Treats platform organically, and inorganically with strategic acquisitions.”CapVest has been investing in food businesses around the world for more over 20 years and has a deep understanding of the consumer food sector. Recent successes include the transformation of Valeo Foods from an Irish-only business with less than €200 million in sales, to a leading global ambient food group with over €1.1 billion in net sales operating in over 106 markets around the world.

CapVest was advised by William Blair (M&A) and Willkie Farr & Gallagher (Legal).

About CapVest

CapVest is a leading international private equity investor that partners with ambitious companies supplying essential goods and services to transform their businesses. As an active and patient investor, CapVest has established a strong record of success in delivering attractive returns by working closely with management in transforming the size and scale of its portfolio companies through a combination of organic and acquisition led growth. For more information, visit www.capvest.co.uk

About Second Nature Brands

Second Nature Brands is a leading creator of snacks and treats that make lives better, naturally. By investing in new product development, thoughtful ingredient sourcing, and innovative business processes, Second Nature Brands is reimagining premium and better-for-you snacks and treats. Under its growing family of brands, Kar’s Nuts®, Second Nature Snacks®, and Sanders Chocolates®, Second Nature Brands has an extensive distribution network across the United States and a growing direct-to-consumer eCommerce presence. Currently, Kar’s Nuts® and Second Nature Snacks® are two of the best-selling trail mix brands in the nation, including the #1 selling Kar’s Sweet ‘n Salty

Mix. Sanders Chocolates is one of the largest kettle-cooked, small-batch crafters of sea salt caramel treats in the U.S. Find out more at Second Nature Brands (www.secondnaturebrandsus.com), Kar’s Nuts (www.karsnuts.com), Second Nature Snacks (www.secondnaturesnacks.com), and Sanders Chocolates (www.sanderscandy.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:
Ben Valdimarsson, Reputation Inc
bvaldimarsson@reputation-inc.com
+44 7889805930

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye